Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OTUB1/USP8-IN-1 HCL 是一种高效的 OTUB1和 USP8 双重抑制剂,具有潜在的抗肿瘤活性,抑制 OTUB1 和 USP8 的活性。OTUB1/USP8-IN-1 可用于研究白血病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,130 | 待询 | ||
5 mg | ¥ 2,490 | 待询 | ||
10 mg | ¥ 3,000 | 待询 | ||
25 mg | ¥ 7,250 | 待询 | ||
50 mg | ¥ 10,600 | 待询 | ||
100 mg | ¥ 14,300 | 待询 |
OTUB1/USP8-IN-1 HCl 的其他形式现货产品:
产品描述 | OTUB1/USP8-IN-1 HCL is a potent dual inhibitor of OTUB1 and USP8 with potential antitumour activity, inhibiting both OTUB1 and USP8. OTUB1/USP8-IN-1 may be used in the study of leukaemia. |
靶点活性 | USP8:0.28 nM, OTUB1:0.17 nM |
体外活性 | OTUB1/USP8-IN-1 (compound 61) exhibits antiproliferative effects in KRAS-WT (H1975, EBC-1, H1703) and KRAS-mutated (H23, A549) NSCLC cell lines when treated with concentrations ranging from 10 nM to 10 μM for 72 hours[1]. Additionally, treatment with OTUB1/USP8-IN-1 at 500 nM for 24 hours leads to a decrease in protein levels of both UBE2N and EGFR in H1975 cells[1]. |
体内活性 | In the H1975 xenograft mouse model, treatment with OTUB1/USP8-IN-1 (compound 61) at concentrations ranging from 10 nM to 10 μM for 72 hours results in a decrease in tumor burden[1]. |
别名 | OTUB1/USP8-IN-1 HCl(2858800-98-1 Free base) |
分子量 | 463.29 |
分子式 | C22H17Cl2FN2O4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OTUB1/USP8-IN-1 HCl Cell Cycle/Checkpoint DNA Damage/DNA Repair Ubiquitination DUB OTUB1/USP8-IN-1 HCl(2858800-98-1 Free base) OTUB1/USP8IN1HCL(2858800981Freebase) Inhibitor inhibitor inhibit